Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
TLDR
In the EU, the highest age-standardised incidence rates for oesophageal cancer are in the Netherlands for men and the UK for women, and variation between countries is high and may reflect different prevalence of risk factors, use of screening and diagnostic methods.About:
This article is published in Annals of Oncology.The article was published on 2013-10-01 and is currently open access. It has received 810 citations till now. The article focuses on the topics: European union & Cancer.read more
Citations
More filters
Journal ArticleDOI
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato,Byoung Chul Cho,Masanobu Takahashi,Morihito Okada,Chen Yuan Lin,Keisho Chin,Shigenori Kadowaki,Myung-Ju Ahn,Yasuo Hamamoto,Yuichiro Doki,Chueh Chuan Yen,Yutaro Kubota,Sung Bae Kim,Chih-Hung Hsu,Eva Holtved,Ioannis Xynos,Mamoru Kodani,Yuko Kitagawa +17 more
TL;DR: Overall survival was significantly improved in the nivolumab group compared with the chemotherapy group, and a favourable safety profile compared with chemotherapy in previously treated advanced oesophageal squamous cell carcinoma patients.
Journal ArticleDOI
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
Hong Yang,Hui Liu,Yuping Chen,Chengchu Zhu,Wentao Fang,Zhentao Yu,Weimin Mao,Jiaqing Xiang,Yongtao Han,Zhijian Chen,Haihua Yang,Jiaming Wang,Qingsong Pang,Xiao Zheng,Huanjun Yang,Tao Li,Florian Lordick,Xavier B. D’Journo,Robert J. Cerfolio,Robert J. Korst,Nuria M. Novoa,Scott J. Swanson,Alessandro Brunelli,Mahmoud Ismail,Hiran C. Fernando,Xu Zhang,Qun Li,Geng Wang,Baofu Chen,Teng Mao,Min Kong,Xufeng Guo,Ting Lin,Mengzhong Liu,Jianhua Fu +34 more
TL;DR: This trial shows that NCRT plus surgery improves survival over surgery alone among patients with locally advanced ESCC, with acceptable and manageable adverse events.
Journal ArticleDOI
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
Thierry Conroy,Marie-Pierre Galais,Jean-Luc Raoul,Olivier Bouché,Sophie Gourgou-Bourgade,Jean-Yves Douillard,Pierre-Luc Etienne,Valérie Boige,Isabelle Martel-Lafay,Pierre Michel,Carmen Llacer-Moscardo,Eric Francois,Gilles Créhange,Meher Ben Abdelghani,Beata Juzyna,Laurent Bedenne,Antoine Adenis +16 more
TL;DR: The PRODIGE5/ACCORD17 trial aimed to assess the efficacy and safety of the FOLFOX treatment regimen versus fluorouracil and cisplatin as part of chemoradiotherapy in patients with localised oesophageal cancer.
Journal ArticleDOI
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
TL;DR: In this paper , the authors compared first-line chemotherapy for advanced esophageal squamous-cell carcinoma with the monoclonal antibody nivolumab plus chemotherapy.
Journal ArticleDOI
Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017.
Jean-Marc Dumonceau,Pierre Henri Deprez,Christian Jenssen,Julio Iglesias-Garcia,Alberto Larghi,Geoffroy Vanbiervliet,Guruprasad P. Aithal,Paolo Giorgio Arcidiacono,Pedro Bastos,Silvia Carrara,László Czakó,Gloria Fernández-Esparrach,Paul Fockens,Angels Ginès,Roald Flesland Havre,Cesare Hassan,Peter Vilmann,Jeanin E. van Hooft,Marcin Polkowski +18 more
TL;DR: ESGE suggests performing EUS-guided sampling for the assessment of regional lymph nodes in T1 (and, depending on local treatment policy, T2) adenocarcinoma and of lesions suspicious for metastasis such as distant LNs, left liver lobe lesions, and suspected peritoneal carcinomatosis.
References
More filters
Journal ArticleDOI
Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus
Michael Stahl,Martin Stuschke,Nils Lehmann,Hans-Joachim Meyer,Martin K. Walz,Siegfried Seeber,Bodo Klump,Wilfried Budach,Reinhard Teichmann,Marcus Schmitt,G. Schmitt,Claus Franke,Hansjochen Wilke +12 more
TL;DR: Tumor response to induction chemotherapy identifies a favorable prognostic group within high-risk patients, regardless of the treatment group, and improves local tumor control but does not increase survival of patients with locally advanced SCC.
Journal ArticleDOI
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis
TL;DR: A significant survival benefit was evident for preoperative chemoradiotherapy and, to a lesser extent, for chemotherapy in patients with adenocarcinoma of the oesophagus and the findings provide an evidence-based framework for the use of neoadjuvant treatment in management decisions.
Journal ArticleDOI
Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102
Laurent Bedenne,Pierre Michel,Olivier Bouché,Chantal Milan,Christophe Mariette,Thierry Conroy,Denis Pezet,Bernard Roullet,Jean-François Seitz,Jean-Philippe Herr,Bernard Paillot,Patrick Arveux,Franck Bonnetain,Christine Binquet +13 more
TL;DR: It is suggested that, in patients with locally advanced thoracic esophageal cancers, especially epidermoid, who respond to chemoradiation, there is no benefit for the addition of surgery after cheMoradiation compared with the continuation of additional chemorADiation.
Journal ArticleDOI
ESPEN Guidelines on Enteral Nutrition: Surgery including Organ Transplantation
Arved Weimann,Marco Braga,László Harsányi,Alessandro Laviano,Olle Ljungqvist,Peter B. Soeters,Karl-Walter Jauch,M. Kemen,J. M. Hiesmayr,T. Horbach,E. R. Kuse,K. H. Vestweber +11 more
TL;DR: These guidelines are intended to give evidence-based recommendations for the use of ONS and TF in surgical patients and it is strongly recommended not to wait until severe undernutrition has developed, but to start EN therapy early, as soon as a nutritional risk becomes apparent.
Journal ArticleDOI
Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction
Michael Stahl,Martin K. Walz,Martin Stuschke,Nils Lehmann,Hans-Joachim Meyer,Jorge Riera-Knorrenschild,Peter Langer,Rita Engenhart-Cabillic,Michael Bitzer,Alfred Königsrainer,Wilfried Budach,Hansjochen Wilke +11 more
TL;DR: Although the study was closed early and statistical significance was not achieved, results point to a survival advantage for preoperative chemoradiotherapy compared with preoperative chemotherapy in adenocarcinomas of the esophagogastric junction.
Related Papers (5)
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joel Shapiro,J. Jan B. van Lanschot,Maarten C.C.M. Hulshof,Pieter van Hagen,Mark I. van Berge Henegouwen,Bas P. L. Wijnhoven,Hanneke W. M. van Laarhoven,Grard A. P. Nieuwenhuijzen,Geke A. P. Hospers,Johannes J. Bonenkamp,Miguel A. Cuesta,Reinoud J. B. Blaisse,Olivier R. Busch,Fiebo J. W. ten Kate,Geert-Jan Creemers,Cornelis J. A. Punt,John T. M. Plukker,Henk M.W. Verheul,Ernst Jan Spillenaar Bilgen,Herman van Dekken,Maurice J.C. van der Sangen,Tom Rozema,Katharina Biermann,Jannet C. Beukema,Anna H.M. Piet,Caroline M. van Rij,Janny G. Reinders,Hugo W. Tilanus,Ewout W. Steyerberg,Ate van der Gaast +29 more